2mg vial
AOD9604 is a modified fragment of the C-terminal region (amino acids 176–191) of human growth hormone (hGH), with an added disulphide bridge to enhance stability. Originally developed as an anti-obesity agent at Monash University, it isolates the fat-mobilising activity of hGH without the growth-promoting, insulin-resistance or IGF-1-elevating effects of the full hormone. It has progressed through Phase 2 clinical trials for obesity and is also studied for cartilage repair and metabolic applications.
Checking availability…
Stimulates lipolysis (breakdown of stored triglycerides) and inhibits lipogenesis (formation of new adipose tissue) via mechanisms distinct from the GH receptor - believed to involve β3-adrenergic receptor pathways in adipose tissue. Does not bind the GH receptor, so it does not elevate IGF-1, impair glucose tolerance or stimulate skeletal growth.
Common research protocols use 250–500mcg subcutaneously once daily, typically administered in a fasted morning state to align with peak lipolytic activity. Cycles often run 8–12 weeks. Higher 500mcg–1mg daily doses are reported in obesity-focused research.
Plasma half-life approx. 30 minutes; biological activity on adipocytes persists longer through downstream signalling.
Reconstitute a 5mg vial with 1–2mL bacteriostatic water for a 2.5–5mg/mL working concentration. Swirl gently down the side of the vial - do not shake.
Lyophilised: 2–8°C, stable approx. 24 months; avoid freeze-thaw cycles. Reconstituted: 2–8°C, protect from light, use within 30 days.
This site contains research-grade peptides information intended for laboratory use only. You must be at least 18 years of age to enter.
For research use only